Kidney biopsy provides an overview of transplanted tissue, while molecular testing adds information about gene activity and patterns associated with rejection or other forms of graft injury. Together with laboratory findings and the patient’s clinical history, these results may support more individualized treatment decisions.
Here, Dave Lowe, Senior Director of Research and Development at Thermo Fisher Scientific, discusses the clinical and technical considerations surrounding molecular testing in kidney transplantation.
What role does molecular testing play in assessing tissue injury in kidney transplant patients?
Molecular testing can provide additional information about the biological processes occurring in a transplanted kidney. Biopsy-based tests measure gene expression in tissue, while other assays analyze blood or urine for patterns associated with rejection or injury.
Kidney biopsy and histology remain central to evaluating graft dysfunction, but they have limitations. A biopsy samples only a small part of the organ, and some findings can be difficult to interpret consistently. Blood markers such as creatinine and estimated glomerular filtration rate indicate how well the kidney is functioning but do not explain why its function has changed.
Molecular testing can complement these methods by providing information about biological activity in the sampled tissue. Some molecular patterns may be detectable when microscopic changes are subtle, although this is not guaranteed, and molecular results do not always establish the cause of injury. They must therefore be interpreted alongside histology, laboratory findings, and the broader clinical picture.
What does it take to develop and validate a molecular diagnostic that can reliably distinguish transplant rejection from other causes of injury?
A central challenge in developing molecular tests is selecting an appropriate reference standard. Histology remains the established clinical standard, but it is not perfect: interpretations can vary, and some biopsy findings occur in several conditions. A molecular test trained solely to reproduce histologic diagnoses may therefore inherit some of these limitations.
Test development requires well-characterized biopsy samples, clearly defined diagnoses, relevant clinical information, and reference cohorts that reflect the intended patient population and clinical setting. Performance should then be assessed using independent samples and, ideally, prospective studies. Researchers must also determine whether using the test changes clinical decisions and improves patient outcomes. Diagnostic accuracy and clinical benefit are related but separate questions.
One example is the Molecular Microscope Diagnostic System (MMDx). MMDx Kidney uses microarray technology to measure gene expression in a biopsy specimen. Algorithms compare the findings with an organ-specific reference dataset and estimate the probability of molecular patterns associated with rejection or injury. The results are intended to complement the broader clinical assessment rather than independently identify every possible cause of graft dysfunction.
Why is identifying the cause of kidney injury important for diagnosis and patient management?
A rise in creatinine can indicate a change in kidney function, but it does not reveal the cause. Possible explanations include rejection, infection, medication toxicity, reduced blood flow, obstruction, or recurrence of the original kidney disease. Because these conditions may require different treatments, distinguishing among them is important.
A biopsy can locate tissue changes and help clinicians assess possible causes, but it samples only a small part of the organ. Molecular analysis can provide additional information about biological activity within that specimen, although it cannot map the entire kidney or overcome the limitations of biopsy sampling.
Interpreting molecular findings alongside histology, laboratory results, and the patient’s clinical history may help clinicians narrow the possible causes and determine the appropriate next steps.
What are the risks of treating a patient for rejection when tissue injury is actually being driven by another process?
Treatment depends on the cause of graft dysfunction. Rejection is often managed by increasing or changing immunosuppression, but this approach could impair the patient’s ability to control an infection if infection is responsible for the injury. Medication toxicity and other causes may require different management.
Immunosuppressive therapies also carry risks, including infection, certain cancers, and drug toxicity. These risks vary according to the medication, dose, and duration of treatment. Clinicians must therefore consider the complete diagnostic picture before changing therapy; no single test result provides a definitive answer.
How can molecular testing complement existing clinical laboratory tests to provide a clearer picture of transplant health?
Routine tests answer different clinical questions. Creatinine and estimated glomerular filtration rate monitor kidney function, while tacrolimus levels indicate exposure to that medication. Donor-specific antibodies suggest an immune response associated with increased risk, but their presence alone does not confirm active rejection.
Depending on the assay and specimen type, molecular tests can provide additional information about tissue injury or immune activity. Combining these results with routine testing may help clinicians decide when further evaluation, including a biopsy, is appropriate. Blood- and urine-based biomarkers are being investigated for monitoring and risk assessment, but current evidence does not support using them as universal replacements for biopsy.
How can analyzing gene activity support more personalized diagnoses and treatment decisions for kidney transplant patients?
Gene-expression testing can reveal biological activity within sampled tissue. Two biopsies with similar histologic findings may show different molecular patterns, providing additional context when clinicians assess rejection or other forms of injury.
These findings may support a more individualized evaluation by indicating whether a pattern is consistent with active rejection or another type of graft injury. Molecular measurements can also be tracked over time, although their role in guiding treatment or medication dosing is still being established. Decisions should therefore integrate molecular results with histology, laboratory findings, and the patient’s clinical condition.
Where is molecular testing in kidney transplantation heading, and which developments are likely to have the greatest clinical impact?
Less invasive monitoring using blood- or urine-based biomarkers is a promising area of research. These tests may help identify patients who require further evaluation or support decisions about when to perform a biopsy. However, studies must establish whether they can guide these decisions safely and improve patient outcomes. Current evidence does not support their use as universal replacements for biopsy.
Another priority is improving the distinction between rejection and other forms of graft injury. More precise characterization could help clinicians avoid treatments that are unlikely to benefit the patient and target management toward the most likely cause. Clinical studies will be needed to determine whether these approaches reduce complications or improve graft outcomes.
